Umicore expands North American presence

Sets up Business Development team to grow sales in the region

Umicore Precious Metals Chemistry has formed a new business development team to expand its sales in the chemical, life sciences, electronic and solar industries in North America.

Phillip Chalabi will lead the team as director, business development North America. Prior to joining the firm, Chalabi was vp of business development for Solvias and responsible for developing Solvias’ catalysis products business in the US.

Don Zeng and Eric Frueh will also join the team and report to Chalabi. Zeng joins Umicore from Heraeus where he was sales and marketing manager for the Americas and Asian market. Freuh has spent more than 24 years at Umicore Precious Metals Chemistry, including the last eight years as sales manager in the US, and expands its responsibilities by joining the team.

You may also like

Media

Brenntag North America announces collaboration with Umicore

The partnership will focus on the distribution of polyurethane and polyester catalysts
Ingredients

Umicore receives world first CEP-certificate for zinc oxide

EDQM grants Umicore the world’s first CEP-Certificate of Suitability for zinc oxide
Ingredients

Umicore’s Argentinian facility for anticancer APIs passes first European cGMP audit

Materials group has been making further improvements to the plant in Pilar, Buenos Aires
Ingredients

Umicore targets 30% market share in platinum APIs

<p>Umicore, a developer of metal based APIs for the pharmaceutical industry, has built a US$10m platinum based API plant in Buenos Aires, Argentina in an effort to improve quality and become a market leader in platinum APIs.</p>
Ingredients

SiliCycle to distribute Umicore's precious metal-based catalysts in North America

<p>Canada-based SiliCycle, a fine chemistry company specialising in silica-based products, is to sell Belgium-based Umicore\'s precious metal-based homogenous catalysts to the North American life science industry.</p>
Research & Development

Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates

The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Manufacturing

Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities

Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Subscribe now